Turning Point Therapeutics falls as science chief resigns

Vadzim Kushniarou/iStock via Getty Images

• The shares of clinical-stage biotech, Turning Point Therapeutics (NASDAQ:TPTX), is trading ~6% lower on Friday after the precision oncology company announced the resignation of its Executive Vice President and Chief Scientific Officer, Siegfried Reich.
• On Feb. 28, Dr. Reich informed of his decision to resign effective Mar. 04, Turning Point (TPTX) disclosed in a regulatory filing on Friday.
• Before joining Turning Point in March 2020, Dr. Reich was the senior vice president of research and co-founder of eFFECTOR Therapeutics, where he led the efforts to discover three first-in-class small-molecule inhibitors.
• At the time, he had over 25 years of industry experience, with the development of more than 20 drug candidates, including licensed drugs, Viracept for HIV, and Inlyta for kidney cancer.